These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28919201)

  • 1. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
    Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
    Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
    Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
    Lancet Respir Med; 2024 Apr; 12(4):e21-e30. PubMed ID: 38548406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macitentan in pulmonary hypertension due to left ventricular dysfunction.
    Vachiéry JL; Delcroix M; Al-Hiti H; Efficace M; Hutyra M; Lack G; Papadakis K; Rubin LJ
    Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29437943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
    Jaïs X; Brenot P; Bouvaist H; Jevnikar M; Canuet M; Chabanne C; Chaouat A; Cottin V; De Groote P; Favrolt N; Horeau-Langlard D; Magro P; Savale L; Prévot G; Renard S; Sitbon O; Parent F; Trésorier R; Tromeur C; Piedvache C; Grimaldi L; Fadel E; Montani D; Humbert M; Simonneau G
    Lancet Respir Med; 2022 Oct; 10(10):961-971. PubMed ID: 35926542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
    Frantz RP; McLaughlin VV; Sahay S; Escribano Subías P; Zolty RL; Benza RL; Channick RN; Chin KM; Hemnes AR; Howard LS; Sitbon O; Vachiéry JL; Zamanian RT; Cravets M; Roscigno RF; Mottola D; Osterhout R; Bruey JM; Elman E; Tompkins CA; Parsley E; Aranda R; Zisman LS; Ghofrani HA;
    Lancet Respir Med; 2024 Jul; 12(7):523-534. PubMed ID: 38705167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
    Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
    Krause A; Zisowsky J; Dingemanse J
    Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
    Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
    Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
    Kim NH; Channick R; Delcroix M; Madani M; Pepke-Zaba J; Borissoff JI; Easton V; Gesang S; Richard D; Ghofrani HA
    Eur Respir J; 2024 Oct; 64(4):. PubMed ID: 39326918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term real world clinical outcomes of macitentan therapy in chronic thromboembolic pulmonary hypertension.
    van Thor MCJ; Ten Klooster L; Snijder RJ; Mager JJ; Post MC
    Respir Med; 2020 Jun; 167():105966. PubMed ID: 32421542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
    Martynyuk TV; Nakonechnikov SN; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.